Mird-237 ((new)) Jun 2026

Provide pharmaceutical researchers with hyper-accurate data models to push new radioligand therapies through clinical trials faster.

While traditional MIRD calculations have long provided the foundational mathematics for assessing radiation risks and therapeutic benefits, MIRD-237 pushes the boundaries by integrating real-time, patient-specific voxel dosimetry. Instead of relying on standardized organ mass estimates, this advanced framework utilizes artificial intelligence to map out exact energy deposition at a cellular level. By adopting the MIRD-237 methodology, clinicians can: Personalize Cancer Treatments: MIRD-237

The number "237" likely denotes the report number within the series, suggesting it addresses a particular aspect of internal radiation dosimetry. Without more specific details, it's difficult to provide a precise topic or content description for MIRD-237. However, like other reports in the MIRD series, it likely offers valuable information and guidelines for professionals in nuclear medicine and radiation oncology, helping them to assess and manage radiation exposure to patients. By adopting the MIRD-237 methodology